- In May 2026, WisdomTree launched the WisdomTree Physical AI, Humanoids, and Drones Fund (WDRN) on the Cboe BZX with a 0.45% expense ratio, offering rules-based exposure to global companies engaged in physical AI activities such as humanoid robotics, autonomous drones, and AI-enabled manufacturing and logistics.
- A week earlier, WisdomTree also introduced the Efficient Rare Earth Plus Strategic Metals Fund (WDIG) with a 0.55% expense ratio, combining equity and commodity futures exposure to critical metals used in electrification, AI infrastructure, and advanced industrial technologies, underscoring its push into specialized thematic and capital-efficient products.
- We’ll now examine how WisdomTree’s push into physical AI robotics and drones through WDRN could reshape its broader investment narrative.
We've uncovered the 13 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
WisdomTree Investment Narrative Recap
To own WisdomTree today, you need to believe it can turn product innovation in ETFs, alternatives, and digital assets into durable fee-based growth despite industry fee pressure and competition. The latest launches in physical AI (WDRN) and strategic metals (WDIG) add eye-catching themes, but the near term story still hinges more on stabilizing earnings after recent losses and managing the risks tied to digital-asset and tokenization investments. The impact of these new funds on that equation is not yet material.
Among the recent launches, WDIG looks especially relevant alongside WDRN. By pairing strategic metals miners with commodity futures, it broadens WisdomTree’s toolkit in capital efficient and thematic products, which ties directly into the key catalyst of growing ETF and model portfolio adoption. Together, WDIG and WDRN show how WisdomTree is trying to deepen its product shelf around emerging technologies and real assets at a time when fee compression and competition remain front of mind.
Yet, against this expansion into physical AI, humanoids, drones, and critical metals, investors should still pay close attention to the evolving regulatory and execution risks that could...
Read the full narrative on WisdomTree (it's free!)
WisdomTree's narrative projects $770.4 million revenue and $209.0 million earnings by 2029. This requires 16.0% yearly revenue growth and about a $100.6 million earnings increase from $108.4 million today.
Uncover how WisdomTree's forecasts yield a $18.82 fair value, a 3% downside to its current price.
Exploring Other Perspectives
Some of the most optimistic analysts were already assuming revenues near US$621.5 million and earnings above US$224 million by 2028, so this kind of launch could strengthen their view that digital tokenization and model adoption offset the risk that WisdomTree’s push into digital assets and platforms like WisdomTree Prime adds higher upfront costs and profit volatility.
Explore 3 other fair value estimates on WisdomTree - why the stock might be worth less than half the current price!
Reach Your Own Conclusion
Don't just follow the ticker - dig into the data and build a conviction that's truly your own.
- A great starting point for your WisdomTree research is our analysis highlighting 2 key rewards and 3 important warning signs that could impact your investment decision.
- Our free WisdomTree research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate WisdomTree's overall financial health at a glance.
Contemplating Other Strategies?
Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:
- Find 51 companies with promising cash flow potential yet trading below their fair value.
- Uncover the next big thing with 27 elite penny stocks that balance risk and reward.
- AI is about to change healthcare. These 32 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com